Percepta® Bronchial Genomic Classifier
Improving Lung Cancer Screening and Diagnosis

The Percepta Bronchial Genomic Classifier uses advanced genomic technology to help reduce the number of unnecessary surgeries and other procedures that can follow when potentially cancerous lung nodules or lesions are found on CT scans. Lung cancer is the leading cause of cancer deaths in the United States, killing nearly 160,000 Americans each year—more than the next three leading cancers combined.

In 2015, more than eight million Americans at high risk of lung cancer became eligible for annual screening with low-dose CT (LDCT). This screening has been shown to save lives through early detection. One of the biggest concerns in screening, however, is the risk and dilemma of finding nodules that are not clearly benign or cancerous. The Percepta classifier is a valuable tool in this new screening paradigm given its proven ability to help patients avoid unnecessary invasive, risky and expensive surgeries that are often required to obtain an accurate diagnosis. The test identifies patients at low risk for cancer with a high degree of accuracy so that they can avoid a diagnostic surgery.
The Percepta test is backed by strong clinical evidence— including data published in The New England Journal of Medicine—demonstrating its accuracy in identifying patients who are at low risk of cancer following inconclusive results from bronchoscopy, a minimally invasive procedure typically used to assess lung nodules. These patients may then be monitored with CT scans in lieu of undergoing surgery—a frequent next step for these patients. A clinical utility study published in the journal CHEST suggested that use of the test may reduce unnecessary surgeries by 50 percent.

The 23-gene Percepta classifier analyzes genomic changes that occur in the airways of current or former smokers with cancer to assess a patient’s risk of having lung cancer, without the need to test the often-hard-to-reach nodule directly.


Improving Lung Cancer Screening and Diagnosis
Advanced genomic technology backed by strong clinical evidence.